These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23386248)

  • 21. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
    Trials; 2016 Jan; 17():46. PubMed ID: 26811156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
    Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
    Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
    Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
    Biason P; Masier S; Toffoli G
    J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
    Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.
    Garziera M; Virdone S; De Mattia E; Scarabel L; Cecchin E; Polesel J; D'Andrea M; Pella N; Buonadonna A; Favaretto A; Toffoli G
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28653974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
    Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
    Deng B; Jia L; Tan H; Lou Y; Li X; Li Y; Yu L
    J Tradit Chin Med; 2017 Feb; 37(1):35-42. PubMed ID: 29956901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.
    Lankisch TO; Schulz C; Zwingers T; Erichsen TJ; Manns MP; Heinemann V; Strassburg CP
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):695-701. PubMed ID: 18349289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous
    Tsai HL; Chen PJ; Chen YC; Li CC; Chang TK; Su WC; Yin TC; Huang CW; Wang JY
    J Int Med Res; 2022 Jul; 50(7):3000605221110697. PubMed ID: 35822291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
    Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Matsunaga M; Araki K; Tanaka R; Ichikawa W; Miya T; Narabayashi M; Akiyama Y; Kawara K; Ando Y; Sasaki Y
    Biol Pharm Bull; 2008 Nov; 31(11):2137-42. PubMed ID: 18981587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
    Kanesada K; Tsunedomi R; Hazama S; Ogihara H; Hamamoto Y; Shindo Y; Matsui H; Tokumitsu Y; Yoshida S; Iida M; Suzuki N; Takeda S; Ioka T; Nagano H
    Cancer Med; 2023 Feb; 12(4):4294-4305. PubMed ID: 36308049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
    Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
    Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
    Yamashita K; Nagashima F; Fujita K; Yamamoto W; Endo H; Miya T; Narabayashi M; Kawara K; Akiyama Y; Ando Y; Ando M; Sasaki Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):204-9. PubMed ID: 20965940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
    Wang Y; Xu JM; Shen L; Xu N; Wang JW; Jiao SC; Zhang JS; Song ST; Li J; Bao HY; Yang L; Li F
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):913-6. PubMed ID: 18478930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
    Aranda E; Valladares M; Martinez-Villacampa M; Benavides M; Gomez A; Massutti B; Marcuello E; Constenla M; Cámara JC; Carrato A; Dueñas R; Reboredo M; Navarro M; Díaz-Rubio E
    Ann Oncol; 2009 Feb; 20(2):251-7. PubMed ID: 18718892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
    Pichereau S; Le Louarn A; Lecomte T; Blasco H; Le Guellec C; Bourgoin H
    J Pharm Pharm Sci; 2010; 13(4):615-25. PubMed ID: 21486535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
    Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
    Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
    Hirata K; Nagata N; Kato T; Okuyama Y; Andoh H; Takahashi K; Oba K; Sakamoto J; Hazama S; Mishima H
    Anticancer Res; 2014 Jan; 34(1):195-201. PubMed ID: 24403462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.